2015 加拿大糖尿病诊疗指南.pdfVIP

Can J Diabetes 39 (2015) 250e252 Contents lists available at ScienceDirect Canadian Journal of Diabetes journal homepage: Commentary Policies, Guidelines and Consensus Statements: Pharmacologic Management of Type 2 Diabetese2015 Interim Update Canadian Diabetes Association Clinical Practice Guidelines Expert Committee The initial draft of this commentary was prepared by William Harper MD, FRCPC, Maureen Clement MD, CCFP, Ronald Goldenberg MD, FRCPC, FACE, Amir Hanna MB, BCh, FRCPC, FACP, Andrea Main BScPhm, CDE, Ravi Retnakaran MD, MSc, FRCPC, Diana Sherifali RN, PhD, CDE, Vincent Woo MD, FRCPC, Jean-François Yale MD, CSPQ, FRCPC, and Alice Y.Y. Cheng MD, FRCPC on behalf of the Steering Committee for the Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada a r t i c l e i n f o Article history: Received 13 May 2015 Accepted 13 May 2015 The process of the development of the Canadian Diabetes inhibitors generally have similar or slightly better efficacy in Association 2013 Clinical Practice Guidelines for the Prevention and lowering glycated hemoglobin levels than do other anti- Management of Diabetes in Canada included provisions to update hyperglycemic agents (5,6). The incidence of hypoglycemia with individual chapters prior to the planned published revision in 2018 SGLT2 inhibitors is rare unless they are used in combination with (1). An updated literature search that focused on new evidence insulin or sulfonylureas (3). Because of the glycosuria resulting published since the development of the 2013 guidelines yielded from the use of these agen